Pharmaceutical Executive-04-01-2016

European pharma is bracing itself for EFPIA’s June deadline requiring the disclosure of transfer-of-value transactions make to HCPs. Pharm Exec looks at how the industry is preparing for this historic moment.

Limitations of the Drug Supply Chain Security Act for pharma-and three strategies to fix them.

Charting two years of collaborative progress in clinical trial data sharing.

Pharm Exec profiles Roche’s Jennifer Cook, this year’s winner of the Healthcare Businesswomen’s Association Woman of the Year award, who has built a career in close parallel to the rise of biotech as a mainstream and integral driver of global health innovation.

The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .

Why the industry needs more women in senior management roles-and the three strategies to get there.

How the DIA, a key industry NGO, is repositioning itself as the go-to place for the independent knowledge-driven insights that drive decisions in a business with no boundaries. One world. One table. Open seating.

Altruism and self-interest are at the heart of European thinking on neglected diseases.

The courts, pharma, and policymakers push FDA to rethink communications policy.

The practice’s emerging-if improbable-cost-saving potential.

The challenges facing the ad industry and big Pharma are remarkably similar-a point driven home by four distinct themes at this year's 4A's Transformation conference illustrate.

Egypt is not just a sun-soaked paradise defined by pyramids and tombs, or-alternatively-a hotbed for political turmoil and revolution. It’s also a vibrant and growing market for pharmaceuticals, experts contend.

Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.